Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com
Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a research report sent to investors on Tuesday morning. The firm issued a hold rating on the biotechnology company's stock.
證券新聞網開始對股票的報導 納布里瓦治療學 (NASDAQ: NBRV — 獲得評分) 在週二早上發送給投資者的研究報告中。該公司對生物技術公司的股票發出了持有評級。
Separately, Northland Securities lowered Nabriva Therapeutics from an outperform rating to an underperform rating in a research note on Friday, January 6th.
另外，北國證券在 1 月 6 日（星期五）的研究報告中將 Nabriva 治療學從「跑贏大市」評級降至「表現不佳」評級。
Nabriva Therapeutics Trading Down 0.5 %
納布里瓦治療學交易下降 0.5%
Shares of NASDAQ:NBRV opened at $1.55 on Tuesday. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $13.65. The firm has a market capitalization of $47.49 million, a price-to-earnings ratio of -0.08 and a beta of 1.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.20 and a quick ratio of 1.40. The business's 50 day moving average price is $1.93 and its 200-day moving average price is $3.69.
納斯達克：NBRV 的股票在周二 1.55 美元開盤。納布里瓦治療學具有 1 年低點 1.22 美元和 1 年高點 13.65 美元。該公司的市值為 4,749 萬美元，價格與收益比為 -0.08，測試版為 1.67。該公司的債務與權益比率為 0.02，流動比率為 2.20，快速比率為 1.40。該企業的 50 天移動平均價格為 1.93 美元，其 200 天移動平均價為 3.69 美元。
Hedge Funds Weigh In On Nabriva Therapeutics
對沖基金權衡納布里瓦治療
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned about 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. 0.23% of the stock is owned by hedge funds and other institutional investors.
一名機構投資者最近提出了在 Nabriva 治療學股票的地位。根據最近與證券交易委員會的披露，文藝復興技術有限責任公司（NASDAQ：NBRV-獲得評級）在第二季度增加了 102.1％ 的股份持有量。該基金在本季度額外收購 402,144 股股份後，擁有該生物技術公司股票的 795,938 股。在最近的報告期結束時，文藝復興技術有限責任公司擁有約 0.13％ 的納布里瓦治療學價值 145,000 美元。0.23％ 的股票由對沖基金和其他機構投資者擁有。
Nabriva Therapeutics Company Profile
納布里瓦治療公司簡介
(Get Rating)
(取得評分)
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Nabriva Theraptics Plc 是一家生物製藥公司，致力於治療嚴重感染的新型抗感染藥物的研究，開發和商業化。其產品管線包括利福霉素、聯盟和 BC-7013。該公司成立於 2005 年 10 月，總部位於愛爾蘭都柏林。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- 獲取有關納布里瓦治療學（NBRV）的研究報告的免費副本
- 埃克森美孚股票：在買入點的醒目距離內
- 高股息收益的必和必拓認為中國推動 23 年增長
- Airbnb 是否正在設置上漲 38％，正如分析師的預測？
- 特斯拉車輛的降價是否意味著 TSLA 股票相同？
- 微軟裁員信號裁員為其他科技公司？
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收納布里瓦治療學的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Nabriva 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。